Ibrutinib is a Bruton’s tyrosine kinase inhibitor (BTKi) approved by the FDA in 2013 and added to the complimentary list of the EML for the treatment of chronic lymphocytic leukaemia. Ibrutinib demonstrated major benefits compared to chemo-immunotherapy. The EML expert committee recommended to MPP to explore ibrutinib for licensing.